for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Accelerate Diagnostics Inc

AXDX.OQ

前日終値

16.59USD

変化

0.38(+2.34%)

出来高

35,590

本日のレンジ

16.00

 - 

16.80

52週レンジ

10.25

 - 

24.00

∙ 約15分前の相場を表示しています。

適時開示

Accelerate Diagnostics Reports Q3 Loss Per Share Of $0.37

Nov 7 (Reuters) - Accelerate Diagnostics Inc <AXDX.O>::ACCELERATE DIAGNOSTICS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.37.Q3 SALES $2.3 MILLION VERSUS $1.4 MILLION.Q3 REVENUE ESTIMATE $3.1 MILLION -- REFINITIV IBES DATA.Q3 EARNINGS PER SHARE ESTIMATE $-0.38 -- REFINITIV IBES DATA.

Accelerate Diagnostics says On Aug 20, Co And Entity Affiliated With Phillips Entered Into Securities Purchase Agreement

Aug 21 (Reuters) - Accelerate Diagnostics Inc <AXDX.O>::ACCELERATE DIAGNOSTICS INC - ON AUG 20, CO AND ENTITY AFFILIATED WITH PHILLIPS ENTERED INTO SECURITIES PURCHASE AGREEMENT.ACCELERATE DIAGNOSTICS INC - PURCHASE AGREEMENT FOR ISSUANCE, SALE BY CO OF AGGREGATE OF 55,586 SHARES OF CO'S COMMON STOCK IN OFFERING.ACCELERATE DIAGNOSTICS - SHARES WERE SOLD AT PURCHASE PRICE OF $17.99 PER SHARE.

Accelerate Diagnostics Reports Q2 Loss Per Share $0.38

Aug 8 (Reuters) - Accelerate Diagnostics Inc <AXDX.O>::ACCELERATE DIAGNOSTICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.38.Q2 SALES $1.8 MILLION VERSUS $1.7 MILLION.Q2 REVENUE ESTIMATE $2.5 MILLION -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE ESTIMATE $-0.39 -- REFINITIV IBES DATA.ACCELERATE DIAGNOSTICS - ACHIEVED MIXED RESULTS IN Q2, AS REVENUE, PLACEMENTS WERE LIGHTER THAN EXPECTED DUE TO LOWER-THAN-EXPECTED CAPITAL SALES IN EMEA.

Accelerate Diagnostics Q1 Loss Per Share $0.40

May 9 (Reuters) - Accelerate Diagnostics Inc <AXDX.O>::ACCELERATE DIAGNOSTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.40.Q1 SALES $1.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $2.1 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.41 -- REFINITIV IBES DATA.

Accelerate Diagnostics Q4 Loss Per Share $0.41

Feb 19 (Reuters) - Accelerate Diagnostics Inc <AXDX.O>::ACCELERATE DIAGNOSTICS REPORTS 2018 FOURTH QUARTER AND FULL-YEAR FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.41.Q4 SALES $1.8 MILLION VERSUS $2.1 MILLION.Q4 REVENUE ESTIMATE $2.6 MILLION -- REFINITIV IBES DATA.Q4 EARNINGS PER SHARE ESTIMATE $-0.41 -- REFINITIV IBES DATA.

Accelerate Diagnostics Sees Q4 Revenue About $1.8 Mln

Jan 6 (Reuters) - Accelerate Diagnostics Inc <AXDX.O>::ACCELERATE DIAGNOSTICS ANNOUNCES PRELIMINARY 2018 FOURTH QUARTER AND FULL-YEAR FINANCIAL RESULTS.SEES Q4 REVENUE ABOUT $1.8 MILLION.SEES FY 2018 REVENUE $5.7 MILLION.ACCELERATE DIAGNOSTICS - NET CASH USED, EXCLUDING FINANCING, IS EXPECTED TO BE APPROXIMATELY $14.1 MILLION FOR Q4 AND $64.1 MILLION FOR FULL-YEAR 2018.

Accelerate Diagnostics Qtrly Net Loss Per Share $0.41

Nov 6 (Reuters) - Accelerate Diagnostics Inc <AXDX.O>::ACCELERATE DIAGNOSTICS REPORTS Q3 2018 FINANCIAL RESULTS.Q3 SALES $1.3 MILLION VERSUS $828,000.Q3 REVENUE VIEW $2.9 MILLION -- THOMSON REUTERS I/B/E/S.QTRLY NET LOSS PER SHARE $0.41.Q3 EARNINGS PER SHARE VIEW $-0.41 -- THOMSON REUTERS I/B/E/S.

Accelerate Diagnostics Inc Quarterly Net Loss Per Share $0.43

Aug 6 (Reuters) - Accelerate Diagnostics Inc <AXDX.O>::ACCELERATE DIAGNOSTICS REPORTS Q2 2018 FINANCIAL RESULTS.Q2 REVENUE $1.7 MILLION.Q2 REVENUE VIEW $2.1 MILLION -- THOMSON REUTERS I/B/E/S.QUARTERLY NET LOSS PER SHARE $0.43.

Accelerate Diagnostics Q1 Loss Per Share $0.37

May 9 (Reuters) - Accelerate Diagnostics Inc <AXDX.O>::ACCELERATE DIAGNOSTICS REPORTS Q1 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.37.Q1 REVENUE ROSE 51 PERCENT TO $801,000.Q1 REVENUE VIEW $2.8 MILLION -- THOMSON REUTERS I/B/E/S.Q1 EARNINGS PER SHARE VIEW $-0.32 -- THOMSON REUTERS I/B/E/S.

Accelerate Diagnostics announces pricing of $150 mln notes offering

March 23 (Reuters) - Accelerate Diagnostics Inc <AXDX.O>::ACCELERATE DIAGNOSTICS, INC. ANNOUNCES PRICING OF $150 MILLION CONVERTIBLE NOTES OFFERING.‍PRICING OF $150.0 MILLION AGGREGATE PRINCIPAL AMOUNT OF 2.50% CONVERTIBLE SENIOR NOTES DUE 2023​.ACCELERATE DIAGNOSTICS- ‍AN ENTITY AFFILIATED WITH ONE OF ACCELERATE DIAGNOSTICS'S DIRECTORS HAS AGREED TO PURCHASE AN AGGREGATE OF $30 MILLION OF NOTES​.‍SALE OF NOTES TO INITIAL PURCHASERS EXPECTED TO RESULT IN ABOUT $145.6 MILLION IN NET PROCEEDS TO ACCELERATE DIAGNOSTICS​.

金融情報はリフィニティブから。すべての情報は少なくとも15分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up